Your session is about to expire
← Back to Search
Radiation Therapy for B-Cell Lymphoma
N/A
Recruiting
Led By Chirayu Patel, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 months
Awards & highlights
Study Summary
This trial is studying if a new radiation therapy schedule will be better for people with relapsed/refractory B-cell lymphoma. It could reduce side effects and cost of treatment.
Who is the study for?
This trial is for adults over 18 with B-cell Lymphoma that's come back or hasn't responded to treatment, and who are set to undergo CAR T-cell therapy. They should be able to lay still for the duration of radiation sessions and not have conditions interfering with the study.Check my eligibility
What is being tested?
The study tests a new weekly schedule of Adaptive Bridging Radiation Therapy (ABRT) over five weeks before CAR T-cell therapy in patients with relapsed/refractory B-cell Lymphoma, aiming to improve side effects, time, cost, and effectiveness.See study design
What are the potential side effects?
Potential side effects may include typical reactions from radiation such as skin irritation at the site of treatment, fatigue, nausea, and other symptoms depending on which areas are being targeted by ABRT.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 20 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility: Percent of patients able to undergo ABRT
Secondary outcome measures
Adverse Events
Objective Response Rate (ORR)
Trial Design
1Treatment groups
Experimental Treatment
Group I: 5-5-5 Adaptive Bridging Radiation Therapy (ABRT)Experimental Treatment1 Intervention
5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion
Find a Location
Who is running the clinical trial?
Varian Medical SystemsIndustry Sponsor
60 Previous Clinical Trials
3,774 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,945 Previous Clinical Trials
13,203,868 Total Patients Enrolled
Chirayu Patel, MDPrincipal InvestigatorMassachusetts General Hospital
Share this study with friends
Copy Link
Messenger